Welcome to our dedicated page for IMV news (Ticker: IMV), a resource for investors and traders seeking the latest updates and insights on IMV stock.
IMV Inc. (IMV) delivers groundbreaking immunotherapies through its proprietary DPX platform, targeting cancer and infectious diseases. This page provides investors and researchers with essential updates on clinical advancements, financial developments, and strategic collaborations shaping the future of immune-based treatments.
Access verified reports on IMV’s lead candidate DPX-Survivac in ovarian cancer trials, COVID-19 vaccine progress, and partnership milestones with leading research institutions. Our curated news collection enables informed analysis of IMV’s market position and scientific impact.
Key updates include trial phase transitions, regulatory submissions, intellectual property developments, and financial performance indicators. All content is sourced from official releases to ensure accuracy and compliance with disclosure standards.
Bookmark this page for real-time access to IMV’s evolving story in biopharmaceutical innovation. Check regularly for critical updates affecting both patient care strategies and investment decision-making.
IMV Inc. (NASDAQ: IMV) unveiled its DPX delivery platform at the AACR-NCI-EORTC Virtual Conference, showcasing its ability to provoke stronger and longer-lasting T cell responses than traditional methods. Notable findings include the dual-targeted immunotherapy DPX-SurMAGE, which showed robust immune responses against bladder cancer-associated antigens with a good safety profile in preclinical trials. Key presentations highlighted the platform's versatility and its lead compound, maveropepimut-S, known for generating specific, persistent T cell responses.
IMV Inc. (NASDAQ: IMV) announced that a poster detailing translational data from the DeCidE clinical study in advanced ovarian cancer will be presented at the SITC Annual Meeting from November 10-14, 2021. The poster, titled Identification of potential response predictors to maveropepimut-S, will feature insights into IMV's novel T cell activating immunotherapy. Dr. Oliver Dorigo from Stanford University will present the findings, with public access to full abstracts starting November 9. This event highlights IMV's commitment to advancing cancer immunotherapy research.
IMV Inc. (NASDAQ: IMV) announced acceptance of two abstracts for virtual poster presentations at the AACR-NCI-EORTC Conference from October 7-10, 2021. The first poster highlights the efficacy of survivin peptides in advanced ovarian cancer patients, showcasing a sustained T cell response through the DPX delivery platform. The second poster presents DPX-SurMAGE, targeting bladder cancer with a favorable safety profile in preclinical models. Full abstracts will be available on demand during the conference.
IMV Inc. (NASDAQ: IMV) announced presentations at three investor conferences in September 2021, showcasing their innovative immunotherapy developments for challenging cancers. The Virtual Wells Fargo Healthcare Conference will feature a fireside chat on
IMV Inc. (TSX: IMV; NASDAQ: IMV) reported its financial and operational results for Q2 2021, highlighting a significant transformation aimed at advancing its DPX platform technology and clinical pipeline, particularly in ovarian cancer and DLBCL.
The company’s recent financing raised approximately $25 million, enhancing its cash position to about $45.8 million post-offering. Despite increased R&D and administrative expenses, IMV's net loss was $7.4 million, up from $4.8 million in Q2 2020. Key leadership changes include the appointment of Andrew Hall as Interim CEO and new scientific advisors to guide clinical development.
IMV Inc. (NASDAQ: IMV) announced positive final topline results from the DeCidE1 Phase 2 trial of maveropepimut-S (MVP-S) for advanced recurrent ovarian cancer. With a 44.9% overall survival rate at 23.8 months and a median survival of 19.9 months, the results are promising for heavily pre-treated subjects, 57.9% of whom were platinum resistant. The trial demonstrated that MVP-S effectively generates tumor antigen-specific T cells, supporting further clinical exploration. Results will inform an upcoming Phase 2 study submission to the FDA.
IMV Inc. (Nasdaq:IMV) has announced the immediate resignation of Frederic Ors as CEO, with Andrew Hall stepping in as Interim CEO while a search for a permanent leader is conducted. Board Chairman Andy Sheldon praised Ors for his contributions, particularly in establishing the proprietary DPX immune-oncology platform and the successful clinical trials of maveropepimut-S. IMV plans to continue advancing its proprietary DPX programs, with several important clinical trials upcoming, aiming to solidify its position in oncology immunotherapy.
IMV Inc. (Nasdaq: IMV) announced a conference call scheduled for August 11, 2021, at 8:00 a.m. ET to discuss its Q2 2021 financial and operational results. Analysts can join by calling (866) 211-3204 or (647) 689-6600, with conference ID 2877244. The call will also be available via a live audio webcast. IMV focuses on innovative cancer immunotherapies, notably its lead candidate, maveropepimut-S, aimed at treating hard-to-treat cancers like breast and ovarian cancer. The company emphasizes the importance of clinical trial outcomes and regulatory approvals for its strategic development.
IMV Inc. (Nasdaq: IMV; TSX: IMV), a clinical-stage biopharmaceutical company focused on developing immunotherapies for hard-to-treat cancers, announced its participation at the BTIG Virtual Biotechnology Conference on August 9-10. The executive management team will engage in a fireside chat hosted by BTIG's research team on August 10 at 11:00 am (ET). A link to the presentation will be available in the investor section of IMV’s website for 30 days post-event. IMV is known for its lead candidate, maveropepimut-S, targeting survivin in various cancers.
IMV Inc. (NASDAQ: IMV) has successfully closed its underwritten public offering of 14,285,714 units at a price of US$1.75 per unit, generating approximately US$25 million in gross proceeds. Each unit consists of one common share and three-quarters of a warrant, with full warrant exercise potentially raising an additional US$22.5 million. Proceeds will fund the clinical development of various cancer therapies, including maveropepimut-S and a new product, DPX-SurMAGE, as well as support the company's proprietary drug delivery platform.
FAQ
What is the market cap of IMV (IMV)?
